A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT01044186
Collaborator
(none)
30
18
1
1.7

Study Details

Study Description

Brief Summary

The purpose of this open-label, non-comparative, multi-center protocol was to further evaluate safety and to provide treatment with ICL670 to patients who had or were at risk of life threatening complications due to transfusional iron overload with a documented inability to tolerate any of the commercially available iron chelators due to severe toxicity rendering continued therapy either impossible or hazardous. Patients who were also ineligible for all on-going registration trials with ICL670 were included in the study. In exceptional cases, patients with a degree of iron overload which was not immediately life-threatening and who were ineligible for the registration trials were also enrolled provided they had a well-documented, sound justification for alternative chelation therapy.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity
Study Start Date :
Jun 1, 2003
Actual Primary Completion Date :
Dec 1, 2007

Arms and Interventions

Arm Intervention/Treatment
Experimental: ICL670

Drug: ICL670

Outcome Measures

Primary Outcome Measures

  1. To evaluate the safety profile and to provide treatment with ICL670 for patients with or at risk of life-threatening complications due to transfusional iron overload who are unable to tolerate other iron chelators because of documented severe toxicity. [0 - 163 weeks]

Secondary Outcome Measures

  1. To estimate the absolute and relative change of liver iron concentration (LIC), to be measured using appropriate methodology available at individual centers. [Yearly]

  2. To evaluate the role of serum ferritin, serum iron, transferrin and transferrin saturation in monitoring iron burden in these patients. [Quarterly]

  3. To evaluate the relationship between changes in LIC and serum ferritin, transferring saturation and serum iron. [Yearly]

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients had to be at risk of life-threatening complications due to transfusional iron overload and be unable to tolerate therapy with any of the commercially available iron chelators (mainly deferoxamine and/or deferiprone) because of documented severe toxicity.

  • Patients with a degree of iron overload which was not immediately life-threatening and who were ineligible for other trials with ICL670 could also be enrolled providing they had a well-documented, sound justification for alternative chelation therapy.

  • Serum ferritin ≥ 8000 μg/L.

  • Serum ferritin < 8000μg/L and LIC of ≥ 7 mg Fe/g dry weight.

  • Patients for whom ≥ 8 blood transfusions per year were required in order to maintain the Hemoglobin level at > 9 g/dL.

  • Female patients who have reached menarche and who were sexually active had to use double barrier contraception (oral plus barrier contraception), or had to have undergone total hysterectomy and/or ovariectomy, or tubal ligation.

  • Written, voluntary informed consent.

Exclusion Criteria:
  • Patients with transfusional iron overload who were not experiencing severe toxicities during therapy with other iron chelators (e.g. deferoxamine and/or deferiprone).

  • Patients with non-transfusional hemosiderosis.

  • Patients with severe liver failure as defined by a score of ≥ 10 points on the Child-Pugh scale.

  • Patients with serum creatinine 1.5 times the upper limit of normal (ULN) at screening.

  • Patients with a history of nephrotic syndrome.

  • Patients with a diagnosis of clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation therapy.

  • Patients with severe systemic diseases unrelated to iron overload and which would prevent them from undergoing treatment with ICL670.

  • Patients with psychiatric or addictive disorders which prevent them from giving informed consent or undergoing treatment with ICL670.

  • Pregnant or breast feeding patients.

  • Patients treated with systemic investigational drugs within the past four weeks or topical investigational drugs within the past seven days.

  • Any surgical or medical condition which might significantly alter the absorption or excretion of drugs as shown by evidence of any of the following:

  • History of inflammatory bowel disease

  • History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection

  • History of pancreatic injury or pancreatitis; indication of impaired pancreatic function/injury as indicated by abnormal lipase or amylase

  • Patients being considered by the investigator as potentially unreliable and/or not cooperative with regard to the protocol.

  • History of drug or alcohol abuse within the 12 months prior to dosing.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children's Hospital and Research Center - Oakland Oakland California United States 94609
2 Children's Hospital of Orange County Orange California United States 92868
3 Children's Hospital Boston Boston Massachusetts United States 02115
4 Queens Hospital Center Jamaica New York United States 11432
5 New York Presbyterian Hospital/Weill Medical College of Cornell University New York New York United States 10021
6 New York Methodist Hospital New York New York United States 11215
7 Cincinnatti Children's Hospital Medical center Cincinnatti Ohio United States 45229
8 Novartis Investigative Site Houston Texas United States 77030
9 Novartis investigative Site Athens Greece
10 Novartis Investigative Site Ancona Italy
11 Novartis Investigative Site Brindisi Italy
12 Novartis Investigative Site Cagliari Italy
13 Novartis Investigative Site Cosenza Italy
14 Novartis Investigative Site Firenze Italy
15 Novartis Investigative Site Milano Italy
16 Novartis Investigative Site Modena Italy
17 Novartis Investigative Site Napoli Italy
18 Novartis Investigative Site Torino Italy

Sponsors and Collaborators

  • Novartis Pharmaceuticals

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01044186
Other Study ID Numbers:
  • CICL670A0117
  • 2004-002303-32 EudraCT number
First Posted:
Jan 7, 2010
Last Update Posted:
Feb 23, 2017
Last Verified:
Feb 1, 2017

Study Results

No Results Posted as of Feb 23, 2017